Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501059 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
A Phase 3 study of Moderate Risk of CVD, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,546
- Enrollment target
- 20
- Study locations
NCT00501059 is a Phase 3 study of Moderate Risk of CVD that has completed, run by Bayer. The registered enrollment target is 12,546 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT00501059, a Phase 3 study of Moderate Risk of CVD, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,546 participants
- Enrollment target
- 20
- Study locations
Study Summary
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial infarction, fatal and nonfatal stroke and CV death, in a population with no history of known CVD who are at moderate risk of major CHD events (approximately 10-20% 10 year CHD risk). This corresponds to a patient population mean 10-year CVD risk of approximately 30%. Subjects are treated in a standard care setting and may receive treatment for the underlying risk factors as defined by the treating physician. Outcome events will be adjudicated by an Endpoint Adjudication Committee and the study will be monitored by an independent Data Safety Monitoring Board.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aspirin (Acetylsalicylic acid, BAYE4465)
Study Locations (20)
California
- - Fremont
- - Huntington Park
- - Los Angeles
- - Rancho Cucamonga
- - Rolling Hills Estates
- Helping Hands Clinical Trials - Santa Ana
Florida
- Medical Research Trust - Boynton Beach
- - Gainesville
- - Hialeah
- Medical Research Centers of South Florida, Inc. - Hollywood
- Office of Dr.Larry Levinson, DO - Hollywood
- - Kissimmee
Alabama
- - Birmingham
- - Graysville
- - Pell City
Arizona
- - Phoenix
- - Scottsdale
- - Tucson
Arkansas
- - Hot Springs
Delaware
- - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,546 participants |
| Start Date | 2007-07-05 |
| Est. Completion | 2016-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501059
The ClinicalTrials.gov registry entry for NCT00501059 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,546 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate Risk of CVD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00501059 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00501059 about?
NCT00501059 is a clinical study titled "A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease". The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus...
What is the current status of trial NCT00501059?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,546 participants. The study started on 2007-07-05. Estimated completion is 2016-11-15.
What conditions does trial NCT00501059 study?
This clinical trial studies the following conditions: Moderate Risk of CVD.
What interventions are being tested in trial NCT00501059?
The interventions under investigation include: Placebo (DRUG), Aspirin (Acetylsalicylic acid, BAYE4465) (DRUG).
Who is sponsoring clinical trial NCT00501059?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00501059 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.